Jessica is currently Project Manager at Grey Wolf Therapeutics Ltd and has extensive experience working across a range of functional areas within a “semi-virtual” biotech company. She has been involved in world-class drug development projects, from preclinical discovery stage right through to IND-enabling and Phase 1/2 clinical stage. She has over 10 years of experience working in the biotech industry and has provided operational expertise to set up small biotech companies at the point of seed investment and Series A financing. She manages key supplier relationships to keep R&D studies and programs progressing in line with scientific aims, corporate goals and financial budgets.
The highlight of her career has been as Executive Assistant/ Project Coordinator (US & AUS) for Spinifex Pharmaceuticals. Jessica played a role in the success of Spinifex’s acquisition by Novartis in July 2015. This buyout was centered around Spinifex’s lead clinical candidate, EM401,
being developed to potentially treat chronic pain and was one of the largest recorded sales of an Australian biotech company.
Jessica attained BBus. and BSc. (Biotechnology) degrees at the Swinburne University of Technology in Melbourne, Australia.